HLS Cash Flow Coverage Ratios from 2010 to 2024

HLS Stock  CAD 3.65  0.15  4.29%   
HLS Therapeutics Cash Flow Coverage Ratios yearly trend continues to be very stable with very little volatility. Cash Flow Coverage Ratios is likely to drop to 0.17. During the period from 2010 to 2024, HLS Therapeutics Cash Flow Coverage Ratios quarterly data regression pattern had range of 53.827 and standard deviation of  13.83. View All Fundamentals
 
Cash Flow Coverage Ratios  
First Reported
2010-12-31
Previous Quarter
0.18203304
Current Value
0.17
Quarterly Volatility
13.83390364
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check HLS Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among HLS Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 33.5 M, Interest Expense of 9.2 M or Total Revenue of 56.1 M, as well as many indicators such as Price To Sales Ratio of 1.22, Dividend Yield of 0.0102 or PTB Ratio of 0.82. HLS financial statements analysis is a perfect complement when working with HLS Therapeutics Valuation or Volatility modules.
  
This module can also supplement various HLS Therapeutics Technical models . Check out the analysis of HLS Therapeutics Correlation against competitors.

Pair Trading with HLS Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if HLS Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in HLS Therapeutics will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to HLS Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace HLS Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back HLS Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling HLS Therapeutics to buy it.
The correlation of HLS Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as HLS Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if HLS Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for HLS Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in HLS Stock

HLS Therapeutics financial ratios help investors to determine whether HLS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLS with respect to the benefits of owning HLS Therapeutics security.